Swedish Orphan Biovitrum Stock Today
| BIOVF Stock | USD 28.71 1.28 4.27% |
PerformanceInsignificant
| Odds Of DistressLow
|
Swedish Orphan is trading at 28.71 as of the 22nd of March 2025. This is a 4.27% down since the beginning of the trading day. The stock's lowest day price was 28.71. Swedish Orphan has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Swedish Orphan Biovitrum AB , an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. The company has 295.99 M outstanding shares. More on Swedish Orphan Biovitrum
Moving against Swedish Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Swedish Pink Sheet Highlights
| President CEO | Guido Oelkers |
| Business Concentration | Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
Swedish Orphan Biovitrum [BIOVF] is a Pink Sheet which is traded between brokers over the counter. The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.99 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Swedish Orphan's market, we take the total number of its shares issued and multiply it by Swedish Orphan's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Swedish Orphan Biovitrum classifies itself under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 295.99 M outstanding shares.
Swedish Orphan Biovitrum has accumulated about 280.15 M in cash with 5.47 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.04.
Check Swedish Orphan Probability Of Bankruptcy
Ownership AllocationSwedish Orphan Biovitrum shows a total of 295.99 Million outstanding shares. The majority of Swedish Orphan Biovitrum outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Swedish Orphan to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Swedish Orphan Biovitrum. Please pay attention to any change in the institutional holdings of Swedish Orphan Biovitrum as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Swedish Ownership Details
Swedish Orphan Biovitrum Risk Profiles
| Mean Deviation | 0.3537 | |||
| Standard Deviation | 1.23 | |||
| Variance | 1.5 | |||
| Risk Adjusted Performance | 0.0522 |
Swedish Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Swedish Orphan without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Efficient Frontier Now
Efficient FrontierPlot and analyze your portfolio and positions against risk-return landscape of the market. |
| All Next | Launch Module |
Swedish Orphan Corporate Management
| Konstantina Karampela | Director Operations | Profile | |
| Christine Wesstrom | Head Operations | Profile | |
| Thomas Larsen | Head Relations | Profile | |
| Pablo Mora | Head Access | Profile | |
| Armin MD | Head Affairs | Profile | |
| Philip Wood | Head of Haemophilia | Profile |
Other Information on Investing in Swedish Pink Sheet
Swedish Orphan financial ratios help investors to determine whether Swedish Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Swedish with respect to the benefits of owning Swedish Orphan security.